Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

NCT05431582 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Tumors
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer

Interventions

DRUG: ZN-c3
DRUG: Bevacizumab
DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]